Organovo Issues Business Update - Quick Facts

(RTTNews) - Organovo (ONVO) issued a business update. With the closing of the sale of its FXR Program to Lilly (LLY), Organovo has received upfront payments and anticipates future milestone payments. The company believes it is well-positioned to repeat the FXR314 success with another IBD opportunity.

Organovo now expects to establish an operating cadence that leverages existing capital at a rate sufficient to push through the end of fiscal 2026. The company expects to report its full year financials for the fiscal year ended March 31, 2025, on or about June 6-10, 2025.

Shares of Organovo are up 3% in pre-market trade on Thursday.

For More Such Health News, visit rttnews.com.